Article
The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.
Molecular cancer therapeutics - 2 Apr 2026
Ma Jianhui, Hegde Sayee, Sergeeva Masha, Chakraborty Binita, Wardell Suzanne E, McDonnell Donald P, Huang Peter Q, Bunker Kevin D, Doñate Fernando, Lackner Mark R, Samatar Ahmed A
Abstract excerpt
Endocrine therapy has proven to be beneficial for patients with estrogen receptor (ER)-positive, HER2-negative (ER+/HER2-) breast cancer; however, de novo or acquired resistance remains a major clinical challenge. Upon progression, many of the cancers continue to be ER dependent, highlighting the opportunities for novel ER-targeting therapies. Fulvestrant, a selective ER degrader (SERD) that antagonizes and...
Topics
Join the communities discussing this publication.